Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today the appointment of José Trevejo M.D. Ph.D., as Chief Medical Officer and Head of Clinical Pipeline Strategy. In this role, Dr. Trevejo will lead the clinical organization and oversee the advancement of Enveda’s robust pipeline that spans multiple therapeutic areas.
Dr. José Trevejo joins Enveda following a string of recent successes, most recently at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of a novel category-creating ophthalmic treatment along with multiple positive Phase 2 readouts. He brings more than fifteen years of leadership and drug development expertise to Enveda, spanning the entire clinical development process from proof-of-concept through approval and early commercialization. Dr. Trevejo has worked across numerous therapeutic areas, including GI, dermatology, ophthalmology, infectious disease, cardiac and metabolic disease as well as immunology.
“We are incredibly excited to welcome Dr. José Trevejo to our leadership team,” said Viswa Colluru, Ph.D., CEO and Founder of Enveda. “His entrepreneurial spirit is further complemented by the operational excellence that he learned from his time at Vertex, Genentech and other successful biopharma companies. His deep background in shepherding novel therapies successfully through clinical trials will be essential to Enveda’s success as we prepare our first two drug candidates for transition into human clinical trials, with many more close behind.”
“It is a huge honor to be joining Enveda at this transformative phase of the company,” says Dr. Trevejo. “Enveda’s approach to identifying new molecules from nature using AI and then adapting them into novel medicines is compelling. However, Enveda’s platform offers more than just a technological breakthrough in identifying novel chemical entities, as the drug candidates in Enveda’s pipeline have the potential to address high impact diseases for patients across a range of therapeutic areas. I believe Enveda’s approach will potentially offer new hope to these patients, and I am excited by the opportunity to contribute to such an innovative company and culture that represents the cutting edge of drug discovery and development.”
José Trevejo M.D., Ph.D. is a physician-scientist and biotechnology executive who has led organizations in the development of high impact medicines spanning multiple therapeutic areas. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology drug. Dr.Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, Jose held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Jose Trevejo received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D./Ph.D. Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC.